X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Day Lucy | CFO | S - Sale | $1.01 | -8,807 | 75,363 | -10% | -$8,883 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Prior Stephen David | Chief Strategy Officer | S - Sale | $1.01 | -6,462 | 59,086 | -10% | -$6,507 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Chanda Sanjay | Chief Development Officer | S - Sale | $1.01 | -9,251 | 75,823 | -11% | -$9,332 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $1.00 | -24,854 | 152,499 | -14% | -$24,962 | |||||
| DM | 2026-01-05 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $171.30 | -139,414 | 7,351,729 | -2% | -$23,881,618 | |||||
| D | 2026-01-05 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale+OE | $33.25 | -6,000 | 98,981 | -6% | -$199,500 | |||||
| D | 2026-01-05 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $33.25 | -2,647 | 24,353 | -10% | -$88,013 | |||||
| D | 2026-01-05 | NAMS | Newamsterdam Pharma Co N.V. | Somaiya Mayur Ian | CFO | S - Sale+OE | $33.25 | -5,118 | 58,382 | -8% | -$170,174 | |||||
2026-01-05 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $28.98 | -2,490 | 94,120 | -3% | -$72,166 | ||||||
| M | 2026-01-05 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $6.04 | -12,918 | 753,562 | -2% | -$78,011 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $97.24 | -5,160 | 83,388 | -6% | -$501,753 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $97.25 | -7,417 | 58,117 | -11% | -$721,320 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $97.26 | -6,952 | 59,634 | -10% | -$676,158 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Turner Christopher Durant | Chief Medical Officer | S - Sale+OE | $97.25 | -7,417 | 72,630 | -9% | -$721,320 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $97.25 | -7,417 | 99,233 | -7% | -$721,320 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $97.26 | -27,433 | 324,879 | -8% | -$2,668,260 | |||||
| M | 2026-01-05 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.65 | -71,054 | 2,401,243 | -3% | -$45,882 | |||||
| D | 2026-01-05 | CRNX | Crinetics Pharmaceuticals, Inc. | Kalofonos Isabel | Chief Commercial Officer | S - Sale+OE | $55.00 | -2,500 | 834 | -75% | -$137,500 | |||||
2026-01-05 | CLYM | Climb Bio, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $3.50 | +7,111 | 11,300,939 | 0% | +$24,889 | ||||||
| D | 2026-01-05 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $487.38 | -14,625 | 2,648 | -85% | -$7,127,877 | |||||
| D | 2026-01-05 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $487.38 | -7,875 | 2,648 | -75% | -$3,838,085 | |||||
2026-01-06 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $1.11 | -3,925 | 88,273 | -4% | -$4,357 | ||||||
| D | 2026-01-05 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $27.02 | -2,872 | 34,793 | -8% | -$77,601 | |||||
2026-01-05 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $21.41 | -31,823 | 1,268,252 | -2% | -$681,342 | ||||||
| M | 2026-01-05 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $39.74 | -2,476 | 86,311 | -3% | -$98,404 | |||||
2026-01-05 | IRWD | Ironwood Pharmaceuticals Inc | Silver Ronald | Principal Accounting Officer | S - Sale | $4.60 | -35,416 | 276,809 | -11% | -$162,914 | ||||||
2026-01-05 | INDV | Indivior Plc | Ryan Barbara | Dir | P - Purchase | $35.39 | +775 | 1,963 | +65% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Humphreys Keith | Dir | P - Purchase | $35.39 | +775 | 5,802 | +15% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Ninivaggi Daniel A | Dir | P - Purchase | $35.39 | +775 | 16,923 | +5% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Stejbach Mark | Dir | P - Purchase | $35.39 | +775 | 16,847 | +5% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Wheadon David E. | Dir | P - Purchase | $35.39 | +1,771 | 14,395 | +14% | +$62,680 | ||||||
2026-01-05 | ACTU | Actuate Therapeutics, Inc. | Thomson Todd S | Dir, 10% | S - Sale | $5.80 | -280,000 | 2,354,344 | -11% | -$1,624,000 | ||||||
2026-01-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $30.68 | -15,000 | 671,907 | -2% | -$460,134 | ||||||
| D | 2026-01-02 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $16.03 | -9,375 | 25,000 | -27% | -$150,260 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Faga Daniel | Pres, CEO | S - Sale+OE | $43.26 | -15,309 | 458,139 | -3% | -$662,267 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $43.26 | -3,363 | 14,330 | -19% | -$145,483 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $43.26 | -4,219 | 33,303 | -11% | -$182,514 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $43.26 | -2,983 | 13,251 | -18% | -$129,045 | |||||
| D | 2026-01-05 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | S - Sale+OE | $38.10 | -71,339 | 147,295 | -33% | -$2,718,230 | |||||
2026-01-02 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Chief Medical Officer | S - Sale | $38.57 | -1,155 | 50,365 | -2% | -$44,552 | ||||||
2026-01-02 | ATAI | Ataibeckley Inc. | Feilding-Mellen Cosmo | Dir | S - Sale | $3.90 | -39,594 | 7,663,396 | -1% | -$154,377 | ||||||
| DM | 2026-01-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | Chief Accounting Officer | S - Sale+OE | $6.64 | -2,432 | 66,265 | -4% | -$16,147 | |||||
| DM | 2026-01-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CTO | S - Sale+OE | $6.62 | -6,311 | 161,966 | -4% | -$41,804 | |||||
| DM | 2026-01-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale+OE | $6.64 | -5,194 | 97,908 | -5% | -$34,491 | |||||
| DM | 2026-01-02 | BCYC | Bicycle Therapeutics Plc | Milnes Alistair | COO | S - Sale+OE | $6.63 | -6,660 | 136,717 | -5% | -$44,127 | |||||
| DM | 2026-01-02 | BCYC | Bicycle Therapeutics Plc | Young Alethia | CFO | S - Sale+OE | $6.62 | -7,623 | 87,081 | -8% | -$50,489 | |||||
| DM | 2026-01-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale+OE | $6.62 | -21,314 | 618,996 | -3% | -$141,199 | |||||
2026-01-02 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $189.58 | -467 | 43,654 | -1% | -$88,532 | ||||||
| DM | 2026-01-02 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $35.25 | -262,752 | 61,804 | -81% | -$9,261,028 | |||||
| D | 2026-01-05 | XERS | Xeris Biopharma Holdings, Inc. | Shannon John Patrick Jr | See Remarks | S - Sale+OE | $7.08 | -24,907 | 2,797,647 | -1% | -$176,257 | |||||
| D | 2026-01-02 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $79.12 | -23,463 | 30,709 | -43% | -$1,856,325 | |||||
2026-01-02 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $28.96 | -10,000 | 69,744 | -13% | -$289,606 | ||||||
2026-01-05 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale | $24.24 | -1,416 | 59,064 | -2% | -$34,324 | ||||||
| D | 2026-01-05 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $75.55 | -2,266 | 120,901 | -2% | -$171,192 | |||||
| D | 2026-01-05 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $76.00 | -734 | 10,666 | -6% | -$55,784 | |||||
| D | 2026-01-02 | PTCT | Ptc Therapeutics, Inc. | Steele Glenn Jr Md Phd | Dir | S - Sale+OE | $76.35 | -12,000 | 22,500 | -35% | -$916,200 | |||||
| DM | 2026-01-02 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $3.82 | -84,000 | 834,592 | -9% | -$321,134 | |||||
| DM | 2026-01-02 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $3.89 | -60,000 | 7,614 | -89% | -$233,388 | |||||
| DM | 2026-01-02 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $3.87 | -60,000 | 0 | -100% | -$232,402 | |||||
| D | 2026-01-06 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $510.00 | -1,000 | 4,190 | -19% | -$510,000 | |||||
2026-01-05 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $495.01 | -50 | 370 | -12% | -$24,751 | ||||||
| D | 2026-01-02 | GLTO | Galecto, Inc. | Schambye Hans T. | CEO | S - Sale+OE | $21.38 | -700 | 4,682 | -13% | -$14,966 | |||||
2026-01-02 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Dir | S - Sale | $11.87 | -15,000 | 469,864 | -3% | -$178,089 | ||||||
| D | 2026-01-02 | GLTO | Galecto, Inc. | Winslow Garrett | GC | S - Sale+OE | $21.38 | -255 | 1,854 | -12% | -$5,452 | |||||
| D | 2026-01-02 | GLTO | Galecto, Inc. | Firmani Lori | CFO | S - Sale+OE | $21.41 | -135 | 931 | -13% | -$2,890 | |||||
| D | 2026-01-02 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $12.85 | -7,433 | 0 | -100% | -$95,490 | |||||
2026-01-02 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $38.42 | -69,582 | 550,978 | -11% | -$2,673,041 | ||||||
2026-01-02 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.48 | -20,000 | 106,418 | -16% | -$769,650 | ||||||
2026-01-05 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $10.44 | -4,170 | 167,064 | -2% | -$43,543 | ||||||
| D | 2026-01-05 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $171.38 | -12,303 | 94,754 | -11% | -$2,108,507 | |||||
2026-01-05 | APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | S - Sale | $25.53 | -3,020 | 91,206 | -3% | -$77,097 | ||||||
| M | 2026-01-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $42.00 | +2,592 | 457,331 | +1% | +$108,858 | |||||
2026-01-02 | RCKT | Rocket Pharmaceuticals, Inc. | Bjork Elisabeth | Dir | P - Purchase | $3.44 | +10,000 | 50,000 | +25% | +$34,400 | ||||||
| D | 2026-01-02 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $175.20 | -87,290 | 41,754 | -68% | -$15,293,422 | |||||
| M | 2025-12-24 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $35.80 | -2,072 | 7,141 | -22% | -$74,181 | |||||
| E | 2026-01-05 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.78 | -1,390 | 92,189,126 | 0% | -$1,085 | |||||
2026-01-05 | ARWR | Arrowhead Pharmaceuticals, Inc. | O'Brien Patrick | COO | S - Sale | $63.11 | -49,493 | 474,908 | -9% | -$3,123,349 | ||||||
2026-01-05 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $63.11 | -40,164 | 171,958 | -19% | -$2,534,661 | ||||||
2026-01-02 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $66.10 | -13,187 | 3,792,739 | 0% | -$871,703 | ||||||
| D | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Zante Greg | CFO | S - Sale+OE | $32.90 | -57,661 | 189,891 | -23% | -$1,896,969 | |||||
| D | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale+OE | $32.98 | -57,661 | 409,190 | -12% | -$1,901,405 | |||||
| D | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO | S - Sale+OE | $32.96 | -233,409 | 2,499,291 | -9% | -$7,692,121 | |||||
| D | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | Foehr Matthew W | Dir | S - Sale+OE | $35.11 | -16,000 | 135,186 | -11% | -$561,694 | |||||
| D | 2026-01-05 | ZYME | Zymeworks Inc. | Smith Jeffrey T L | EVP, Chief Medical Officer | S - Sale+OE | $25.10 | -10,538 | 18,352 | -36% | -$264,471 | |||||
| D | 2026-01-05 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $25.10 | -54,343 | 193,266 | -22% | -$1,363,841 | |||||
| D | 2026-01-05 | ZYME | Zymeworks Inc. | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $25.10 | -20,110 | 40,391 | -33% | -$504,699 | |||||
| D | 2026-01-02 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale+OE | $78.69 | -6,500 | 37,793 | -15% | -$511,472 | |||||
2026-01-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $7.43 | -16,667 | 1,308,103 | -1% | -$123,776 | ||||||
| D | 2026-01-02 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $500.02 | -1,000 | 4,190 | -19% | -$500,015 | |||||
| D | 2026-01-02 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $100.51 | -10,000 | 49,086 | -17% | -$1,005,114 | |||||
| D | 2026-01-02 | XLO | Xilio Therapeutics, Inc. | Brennan Kevin M. | SVP, FINANCE, ACCOUNTING | S - Sale+OE | $0.64 | -1,826 | 6,371 | -22% | -$1,174 | |||||
| D | 2026-01-02 | XLO | Xilio Therapeutics, Inc. | Frankenfield Christopher James | CFO | S - Sale+OE | $0.64 | -7,030 | 24,766 | -22% | -$4,522 | |||||
| D | 2026-01-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $60.28 | -15,000 | 50,440 | -23% | -$904,200 | |||||
2025-12-31 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $30.05 | -6,567 | 404,075 | -2% | -$197,338 | ||||||
2025-12-31 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $30.05 | -2,840 | 296,991 | -1% | -$85,342 | ||||||
2026-01-02 | RMTI | Rockwell Medical, Inc. | Hunter Heather | COO | S - Sale | $0.84 | -2,868 | 132,523 | -2% | -$2,396 | ||||||
2026-01-02 | RMTI | Rockwell Medical, Inc. | Neri Jesse | SVP, CFO | S - Sale | $0.84 | -886 | 124,842 | -1% | -$740 | ||||||
| D | 2025-12-31 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $4.07 | -8,125 | 0 | -100% | -$33,089 | |||||
2026-01-02 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $22.84 | -3,150 | 91,996 | -3% | -$71,946 | ||||||
2026-01-05 | ALT | Altimmune, Inc. | Sohn Catherine A. | Dir | P - Purchase | $4.24 | +500 | 1,500 | +50% | +$2,118 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |